Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Silexion Therapeutics reported Q2 2026 financials and significant progress on its SIL204 RNAi therapy for KRAS-driven pancreatic cancer, initiating Phase 2/3 clinical trials in Israel and Germany. New preclinical data reveal enhanced immune-sensitization, supporting combination with checkpoint inhibitors. The company also strengthened finances via …